Thiazolidinediones (TZDs) are insulin-sensitizing drugs and are potent agonists of the
nuclear peroxisome proliferator-activated receptor-γ (PPAR-γ). Although muscle is the major …

Impaired estrogen action is associated with the metabolic syndrome in humans. We sought
to determine whether impaired estrogen action in female C57Bl6 mice, produced by whole …

Estrogens play a fundamental role in the physiology of the reproductive, cardiovascular,
skeletal, and central nervous systems. In this report, we review the literature in both rodents and …

Inflammation may underlie the metabolic disorders of insulin resistance and type 2 diabetes.
IκB kinase β (IKK-β, encoded by Ikbkb) is a central coordinator of inflammatory responses …

Impaired estrogen receptor α (ERα) action promotes obesity and metabolic dysfunction in
humans and mice; however, the mechanisms underlying these phenotypes remain unknown. …

The metabolic syndrome is a collection of obesity-related disorders. The peroxisome
proliferator-activated receptors (PPARs) regulate transcription in response to fatty acids and, as …

PPARγ is required for fat cell development and is the molecular target of antidiabetic
thiazolidinediones (TZDs), which exert insulin-sensitizing effects in adipose tissue, skeletal muscle, …

Syndrome X, typified by obesity, insulin resistance (IR), dyslipidemia, and other metabolic
abnormalities, is responsive to antidiabetic thiazolidinediones (TZDs). Peroxisome proliferator-…

Metabolic syndrome (MS) is a collection of cardiometabolic risk factors that includes obesity,
insulin resistance, hypertension, and dyslipidemia. Although there has been significant …

The insulin-sensitizing effects of thiazolidinediones are thought to be mediated through
peroxisome proliferator-activated receptor-γ, a nuclear receptor that is highly abundant in …